- Conditions
- Multiple Myeloma
- Interventions
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 245
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stroke Volume Variation, Diastolic Dysfunction
- Interventions
- Trans thoracic Ultrasound Examination, Intravenous fluid administration
- Procedure · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
- Interventions
- Tissue Sample collection, Blood Sample Collection, Rectal Swab
- Procedure · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Functional Impairment, Functional Performance
- Interventions
- CTraC-FIT, Enhanced Usual Care
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Daily dosing, Time-driven dosing, Event-driven dosing
- Drug
- Lead sponsor
- HIV Prevention Trials Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more
- Conditions
- Esophageal Cancer
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Biological
- Lead sponsor
- Dickran Kazandjian, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cancer
- Interventions
- Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Major Depressive Disorder, Bipolar Depression, Suicidal Ideation
- Interventions
- Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy, Partial Sleep deprivation, Sleep Phase Delay, and Low amber light., Treatment as usual
- Behavioral · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Vyxeos, Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Cergutuzumab Amunaleukin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Nashville, Tennessee
- Conditions
- Solid Tumors and Lymphomas
- Interventions
- MIW815, PDR001
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Houston, Texas + 1 more
- Conditions
- Epilepsy
- Interventions
- Retigabine / Ezogabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Insufficient Sleep, Obesity
- Interventions
- Fixed sleep goal, Personalized sleep goal, Digital sleep health messaging without virtual study visit, Digital sleep health messaging with virtual study visit, Inactive Parent-Directed Loss-Framed Incentive, Active Parent-Directed Loss-Framed Incentive, Inactive Supportive Feedback, Active Supportive Feedback
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
- Interventions
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Drug
- Lead sponsor
- Mohammed Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Excessive Daytime Sleepiness, Narcolepsy
- Interventions
- Placebo, PF-03654746
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
- Conditions
- Small Cell Lung Cancer, Neuroendocrine Carcinoma
- Interventions
- RO7616789, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
- Interventions
- Motivational Interviewing-Based Counseling, Standard Oral Health Education
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cocaine Dependence, Depression
- Interventions
- Mirtazapine, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Interventions
- alpelisib, everolimus, exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • New York, New York
- Conditions
- Solid Tumors
- Interventions
- RO7444973, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- BIIB022 With Paclitaxel and Carboplatin
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Denver, Colorado